Why the study?
Does targeting a higher MAP reduce mortality or improve neurologic recovery in patients after cardiac arrest?
Does targeting a higher MAP reduce mortality or improve neurologic recovery in patients after cardiac arrest?
In an individual patient data meta-analysis, targeting a higher MAP after cardiac arrest did not significantly reduce mortality or improve neurologic recovery compared to a lower MAP target.
No benefit from higher MAP targets post-CA; confirms lower targets suffice and narrows future trials to very large effects.
Targeting a higher MAP compared to a lower MAP is unlikely to reduce mortality or improve neurologic recovery after CA. Only a large treatment effect above 25% (RR < 0.75) could be excluded, and future studies are needed to investigate if relevant but lower treatment effect exists. Targeting a higher MAP was not associated with any increase in adverse effects.
No takes yet. Share an insight, caveat, or question.
Niemelä et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: